NAVLIN Price & Access Data (formerly Pricentric ONE by EVERSANA™) is part of the NAVLIN ecosystem of data, software and insights solutions.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
Follow our showcase page on LinkedIn!
Updates made <24 hours from time of publication
+40 bodies of HTA decisions
99.8% data accuracy
5.5M Price pointsNAVLIN Price & Access Data is updated in real time, providing users with the industry’s most accurate pricing and market access data. Our database manages every product in more than 100 countries and provinces, including complete historical coverage in most countries.
The combination of comprehensive pricing and market access data, one-click insights and expert support enables teams to focus
on strategy and improved decision-making.
Our team of analysts offers 24×7 support and assists in the development of custom reports to meet your most pressing needs.
NAVLIN Price & Access Data provides global pricing, analytics, HTA, regulatory, clinical, and economic data along with news and insights in a single platform.
The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in May. Belgium, Ireland, and the Netherlands will undertake a joint health technology assessment (HTA) of Zolgensma as part of […]
The world is facing a multitude of governing and legislative changes that will directly affect pharmaceutical pricing in the coming years, with many of these changes exacerbated by the pandemic. As countries become increasingly interconnected, decisions in one pharmaceutical market will have ripple effects globally. Reasons for traditional launch sequencing include market size, opportunity and […]
